JP Morgan Chase
SYRS

JP Morgan Chase’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

JP Morgan Chase’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-549
Closed -$127 – 7840
2024
Q4 		$127 Hold
549
– – ﹤0.01% 6977
2024
Q3 		$1.18K Hold
549
– – ﹤0.01% 6702
2024
Q2 		$2.83K Hold
549
– – ﹤0.01% 6481
2024
Q1 		$2.94K Hold
549
– – ﹤0.01% 6533
2023
Q4 		$4.28K Sell
549
-528
-49% -$1.81K ﹤0.01% 6582
2023
Q3 		$4.25K Buy
1,077
+481
+81% +$1.8K ﹤0.01% 6398
2023
Q2 		$1.88K Hold
596
– – ﹤0.01% 6351
2023
Q1 		$2K Hold
596
– – ﹤0.01% 6452
2022
Q4 		$2K Sell
596
-116
-16% -$503 ﹤0.01% 6351
2022
Q3 		$5K Buy
712
+421
+145% +$3.42K ﹤0.01% 6107
2022
Q2 		$3K Sell
291
-3,163
-92% -$29.6K ﹤0.01% 6255
2022
Q1 		$41K Buy
3,454
+677
+24% +$12.1K ﹤0.01% 5873
2021
Q4 		$91K Buy
2,777
+111
+4% +$4.49K ﹤0.01% 5726
2021
Q3 		$120K Sell
2,666
-15,689
-85% -$766K ﹤0.01% 5481
2021
Q2 		$1M Sell
18,355
-48,036
-72% -$2.84M ﹤0.01% 4290
2021
Q1 		$4.97M Sell
66,391
-7,196
-10% -$748K ﹤0.01% 2978
2020
Q4 		$7.98M Buy
73,587
+314
+0.4% +$28.7K ﹤0.01% 2391
2020
Q3 		$7M Sell
73,273
-6,052
-8% -$688K ﹤0.01% 2305
2020
Q2 		$8.46M Sell
79,325
-8,829
-10% -$792K ﹤0.01% 2028
2020
Q1 		$5.23M Sell
88,154
-6,455
-7% -$438K ﹤0.01% 2226
2019
Q4 		$6.54M Buy
94,609
+52,550
+125% +$3.19M ﹤0.01% 2474
2019
Q3 		$4.37M Buy
42,059
+1,275
+3% +$120K ﹤0.01% 2808
2019
Q2 		$3.24M Buy
40,784
+677
+2% +$47.1K ﹤0.01% 3012
2019
Q1 		$3.67M Sell
40,107
-69
-0.2% -$4.81K ﹤0.01% 2850
2018
Q4 		$2.24M Buy
40,176
+3,180
+9% +$242K ﹤0.01% 3203
2018
Q3 		$4.41M Buy
36,996
+829
+2% +$96.2K ﹤0.01% 2839
2018
Q2 		$3.69M Sell
36,167
-1,284
-3% -$159K ﹤0.01% 2930
2018
Q1 		$4.86M Buy
37,451
+4,571
+14% +$500K ﹤0.01% 2599
2017
Q4 		$3.2M Buy
32,880
+20,227
+160% +$2.72M ﹤0.01% 3019
2017
Q3 		$1.93M Buy
12,653
+1,733
+16% +$326K ﹤0.01% 3180
2017
Q2 		$1.76M Sell
10,920
-1,136
-9% -$178K ﹤0.01% 3131
2017
Q1 		$1.92M Sell
12,056
-856
-7% -$104K ﹤0.01% 3061
2016
Q4 		$1.57M Sell
12,912
-729
-5% -$102K ﹤0.01% 3223
2016
Q3 		$1.89M Buy
+13,641
New +$1.73M ﹤0.01% 2823

Other funds holding SYRS

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

JP Morgan Chase's SYRS Position: Q1 2025 in Review

JP Morgan Chase sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 549 shares — an estimated $127 sold.

JP Morgan Chase first reported a position in SYRS in Q3 2016 and held it in 34 quarters. The position peaked at $8.46M in Q2 2020. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.

  • JP Morgan Chase reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • JP Morgan Chase sold 549 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $127.
  • JP Morgan Chase first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2016 and held it in 34 quarters.
  • JP Morgan Chase's Syros Pharmaceuticals, Inc. Common Stock position peaked at $8.46M in Q2 2020.
  • 7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.

Based on JP Morgan Chase's 13F filing for Q1 2025, filed 12 May 2025.